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Abstract
Background: Positron emission tomography (PET) imaging with 68Gallium labeled somatostatin analogues (68Ga-
DOTA-SSA) plays a key role in neuroendocrine tumor management. The impact of patient size on PET image quality
is not well known for PET imaging with 68Ga-DOTA-SSA. The aim of this study is to propose a dose regimen based
on patient size that optimizes image quality and yields sufficient image quality for diagnosis.
Methods: Twenty-one patients (12 males, 9 females) were prospectively included for 68Gallium-DOTA-Tyr3-
Octreotate (68Ga-DOTA-TATE) PET/CT, which was acquired in whole body list mode using 6 min per bed position
(mbp). The list-mode events were randomly sampled to obtain 1 to 6 mbp PET reconstructions. For semi-
quantitative assessment of image quality, the signal-to-noise ratio (SNR) was measured in the liver. The SNR
normalized (SNRnorm) for administered activity and mbp was correlated with body mass, length, body mass index,
body mass/length, and lean body mass. Three experienced nuclear medicine physicians visually graded image
quality using a 4-point scale, and categorically scored the number of somatostatin-receptor positive lesions for each
reconstruction. To investigate the impact of image quality on lesion quantification, the mean, maximum, and peak
standardized uptake values (SUVs) of one abdominal lesion were measured in the 1 to 6 mbp PET reconstructions.
Results: Of all patient-dependent parameters, body mass showed the strongest correlation (R2 = 0.6) with
SNRnorm. Lesion detectability analysis showed no significant difference for 3-5 mbp compared with the complete 6
mbp PET reconstruction. The SUV measurements showed no significant (p > 0.05) differences across the
reconstructions. Visual assessment revealed that an SNR of 6.2 results in PET scans with moderate to good image
quality. A non-linear expression was derived to calculate the required (dose × acquisition time) product (DTP) for
the chosen SNR level of 6.2 that would yield a more constant image quality.
Conclusion: Body mass can be used to predict 68Ga-DOTA-TATE PET image quality. The proposed non-linear dose
regimen based on body mass standardizes the image quality while maintaining sufficient image quality for
diagnosis.
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Background
Neuroendocrine tumors (NETs) are a heterogeneous
group of tumors, originating from neuroendocrine cells,
and are mostly located in the small intestine, pancreas,
and lungs. The majority of these tumors have an overex-
pression of somatostatin receptors (SSTR) on their cell
membrane. Radiolabeled somatostatin analogues (SSA)
with high affinity for SSTR subtype 2 enable in vivo im-
aging of NETs as well as peptide receptor radionuclide
therapy (PRRT) [1, 2]. For years, planar imaging and single
photon emission computed tomography (SPECT) with
111In-pentetreotide (111In-DTPA0-octreotide (OctreoScan,
Mallinckrodt St Louis, USA)) was the most important nu-
clear medicine imaging technique for diagnosis and treat-
ment management of NETs [3, 4]. However, in recent
years, positron emission tomography/computer tomog-
raphy (PET/CT) imaging with Gallium-68 labeled SSA has
become widely available.
The Erasmus Medical Center uses 68Gallium-DOTA-
Tyr3-Octreotate (68Ga-DOTA-TATE), which predomin-
antly binds to SSTR subtype 2 [4, 5]. Its theranostic twin
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is a well-established treatment for NETs [6, 7]. Other com-
monly used tracers are 68Gallium-DOTA-D-Phe1-Tyr3-
Octreotide (68Ga-DOTA-TOC) [8], which also binds to
SSTR subtype 5 and 68Gallium-DOTA-1-Nal3-Octreotide
(68Ga-DOTA-NOC) [9], which binds to SSTR subtypes 2,
3, and 5.
PET imaging provides a higher spatial resolution and
sensitivity compared with SPECT imaging, resulting in
better image quality with shorter acquisition times [4, 5, 8,
10]. PET image quality depends, among others, on the
quality of the PET camera, the tracer distribution, the
amount of administered activity, and the acquisition time
used for scanning [11, 12]. Image quality is also influenced
by patient size, due to a variable amount of attenuation
within patients with different habitus [11, 12]. The admin-
istered activity should be as low as reasonably achievable
(ALARA) to minimize the detriment due to the use of ion-
izing radiation. However, the dosage should be sufficient
to provide acceptable image quality for diagnosis and
semi-quantitative analysis within a reasonable amount of
acquisition time [13].
The 2017 European Association of Nuclear Medicine
(EANM) procedural guideline on PET/CT tumor imaging
with 68Ga-DOTA-SSA recommends an administered ac-
tivity range of 100 to 200 megabecquerel (MBq), depend-
ing on the characteristics of the PET scanner and patient
body weight [14]. However, the impact of body mass or
other patient-dependent parameters, such as body mass
index (BMI) and lean body mass (LBM) on PET image
quality has not previously been investigated for 68Ga-
DOTA-SSA PET/CT.
Several studies have investigated the impact of patient
habitus on 18Fluorine-fluoro-2-deoxyglucose (18F-FDG)
PET/CT image quality. Geismar et al. [15] suggested
adjusting the linear dose regimen with higher 18F-FDG ac-
tivity per kilogram (kg) of body mass or increase PET ac-
quisition time per bed position for obese patients to
achieve more constant image quality [16–19]. A second
possibility is a linear dose regimen for patients below 75
kg and a quadratic dose regimen for patients above 75 kg.
A quadratic dose regimen was proposed by de Groot et al.
[20] in a study to optimize the administered 18F-FDG ac-
tivity as a function of a patient-dependent parameter, for
example, body mass, BMI, LBM, fat mass (defined by body
mass minus the lean body mass), and body mass per body
length. This study showed that a quadratic relationship
between administered activity, body mass, and acquisition
time delivered a more constant PET image quality than a
linear dose regimen for 18F-FDG. Moreover, in a later
study by Menezes et al. [21], body mass was found as best
predictor in a univariate analysis. Furthermore, a multi-
variate analysis in a study by Wickham et al. [12] showed
a combination of body mass, sex, and length as best
predictors. Based on the results of de Groot et al. [20], the
current EANM guideline for tumor imaging with 18F-FDG
[22] recommends adjusting the activity quadratically to
the body mass, but for pragmatic reasons, the guideline
also includes a linear activity-body mass relationship.
Previous phantom studies suggest that 18F-FDG findings
may not necessarily be applicable to 68Ga-DOTA-SSA
PET because the impact of the larger positron range of
3.5 mm (mean range in water) of Gallium-68 on image
quality [23, 24], and the shorter half-life of 68min that
might necessitate a higher injected activity. Furthermore,
68Ga-DOTA-SSA tracer biodistribution differs from 18F-
FDG biodistribution. Therefore, the relationship between
patient-dependent parameters and 68Ga-DOTA-SSA PET
image quality should be investigated. The aim of this study
is to investigate the influence of patient size on 68Ga-
DOTA-SSA PET image quality and to propose a dose
regimen that maintains constant image quality and yields
sufficient image quality for clinical use.
Methods
Patients
For this study, 21 patients (12 men, 9 women; mean age
60.1 ± 10.1 years) that were scheduled for 68Ga-DOTA-
TATE PET/CT at the Erasmus Medical Center for sta-
ging or restaging of NETs, were prospectively included.
Patients were equally distributed according to their
weight into seven different groups (50-60 kg, 61-70 kg,
71-80 kg, 81-90 kg, 91-100 kg, 101-110 kg, 111-120 kg) of
each three patients. Inclusion criteria were diagnosed
with or suspicion of a NET. Exclusion criteria were
claustrophobia, unable to maintain scan position for 36
min and already known extensive liver involvement. The
study was approved by the Medical Ethical Committee
of the Erasmus Medical Center, written informed con-
sent was obtained from all the patients, and procedures
were in accordance with the Declaration of Helsinki of
1964, as revised in 2013.
Patient-dependent parameters
Body mass (kg) and body length (m) were measured be-
fore tracer injection. Three other parameters were calcu-
lated: BMI by dividing body mass (kg) by the square of
length (m2), body mass per body length by dividing the
body mass (kg) by the body length (m), and lean body
mass (LBM) by the approach of Janmahasatian et al. [25].
68Ga-DOTA-TATE PET/CT
Patients were prepared according to the standard protocol,
they were asked to drink 1L of water during the 2 h prior
to injection. When patients used long-acting somatostatin
analogues (e.g., Sandostatine LAR, Novartis Pharma BV),
PET/CT was planned just prior to the next scheduled
monthly dose. 68Ga-DOTA-TATE was intravenously
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injected with an activity of 1.5MBq/kg (128 ± 32.2MBq).
PET images were acquired 61 ± 3min after tracer injection
in supine position with the arms up on a Siemens Bio-
graph mCT PET/CT scanner (Siemens Healthineers, Er-
langen, Germany). According to our local scan protocol,
first a whole-body low dose CT was acquired for attenu-
ation correction and localization purposes (120 kV, quality
reference mAs 40, rotation time 0.5 s, pitch of 0.8mm,
slice thickness of 3mm; reconstructed slice thickness 3
mm and a Siemens B19f low dose for emission computed
tomography kernel). Directly after the low-dose CT, PET
acquisition started in list mode, with an acquisition time of
6 mbp, using 6 to 7 bed positions per patient (from skull
base to inguinal region).
Prior to image reconstruction, the acquired list-mode
PET data were randomly sampled using an in house devel-
oped Python script to simulate PET scans of 1, 2, 3, 4, 5,
and 6 mbp, similar to the method used by Halpern et al.
[16, 17]. All scans were corrected for scatter and attenu-
ation using the low dose CT and reconstructed using or-
dered subset expectation maximization (OSEM) with point
spread function (PSF) recovery, time of flight (TOF), 3 itera-
tions, 21 subsets, a 3mm Gaussian post reconstruction filter
on a matrix of 200 × 200 with a pixel size of 4.1 × 4.1mm.
Image analysis
A volume of interest (VOI) was placed in a lesion-free
homogeneous part of the right liver lobe (diameter 3 cm)
using the Hermes Hybrid viewer 2.6D software (Hermes
Medical Solutions, Stockholm, Sweden). The VOIs were
placed at least 1 cm from the edge of the liver to avoid
partial volume effects. For each patient, VOIs were
placed at the exact same location throughout all 6 PET
reconstructions. As a measure of image quality, the
signal-to-noise ratio (SNR) within the VOI was calcu-
lated by dividing the liver SUVmean (liver biodistribu-
tion) by the standard deviation (SD). The 6 mbp PET
reconstruction served as the reference for comparing the
SNR between reconstructions.
PET image quality depends on the time per bed pos-
ition and the amount of administered activity. The dose-
time product (DTP (MBq·min)) is the product of these
parameters. By assuming Poisson statistics, noise in-
creases with the square root of the signal, the SNR can
be normalized (SNRnorm (MBq·min)−1/2)) for the ad-
ministered activity and scan time per bed position [20].
The SNRnorm is assumed to be independent of scan
time and administered activity.
SNRnorm ¼ SNRffiffiffiffiffiffiffiffiffiffi
DTP
p ð1Þ
To investigate the relation between patient-dependent
parameters and PET image quality, the following
patient-dependent parameters were correlated with the
mean SNRnorm: body mass, length, BMI, body mass per
body length, and LBM. The patient-dependent param-
eter demonstrating the highest correlation was selected
to derive an optimized dose regimen.
In order to compare semi-quantitative measurements
between all reconstructions, standardized uptake value
(SUV) measurements were obtained of one lesion in
each patient with a suspicious lesion located centrally in
the abdomen. VOI-based SUV measurements were per-
formed. SUVmax was measured by the voxel with the
highest pixel value in the VOI, SUVpeak by the 1 cm3
with the highest pixel values inside the VOI [26], and
SUVmean was determined using a region growing algo-
rithm with a 50% threshold of SUVmax [22]. These
VOIs were placed at the exact same position throughout
all PET reconstructions.
All anonymized PET data (21 patients, 5 reconstruc-
tions per patient) were presented to three experienced
nuclear medicine physicians, for visual assessment of
image quality. They were blinded for clinical data.
Reconstructions were presented in the following order
to the physicians: 2, 3, 4, 5, and 6 mbp, to avoid lesion
recognition bias that might be introduced by viewing
images with higher count statistics prior to images with
lower count statistics. Each physician scored all recon-
structions subjectively for visual diagnostic image quality
using the four-point scoring scale from Halpern et al.
[17]: non-diagnostic (0), poor (1), moderate (2), or good
(3). The median of the three scores was taken as a meas-
ure of subjective image quality for each reconstruction.
For lesion detectability, the readers recorded the num-
ber of SSTR positive lesions in neck/thorax, liver, abdo-
men (without liver), and skeleton for each
reconstruction in the following categories: 0 lesions (0),
1 lesion (1), 2 lesions (2), 3-5 lesions (3), 6-10 lesions
(4), and > 10 lesions (5), yielding 252 scores per mbp. In
concordance with the SNR approach, lesion detectability
was compared between all reconstructions with the 6
mbp as a reference.
Statistical analysis
All statistical analyses were performed using IBM SPSS
statistics version 24. To test for significant differences in
liver biodistribution (liver SUVmean), image quality
(SNR and SNRnorm), and lesion quantification (SUV-
max, SUVmean, and SUVpeak) in the 1 to 6 mbp recon-
structions, a repeated measures analysis of variance
(ANOVA) (α = 0.05) (including Mauchly’s test of spher-
icity with a Greenhouse-Geisser correction for non-
sphericity) or a non-parametric Friedman test (α = 0.05)
after testing the data for normality by a Kolmogorov
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Smirnov test was performed. The Bonferroni multiple
comparison post hoc test or the non-parametric post
hoc Dunn-Bonferroni test was used to identify signifi-
cant differences between 1-5 mbp reconstructions and
the 6 mbp reconstruction.
The coefficient of determination (R2) was used to se-
lect the best patient-dependent parameter after correl-
ation of each parameter with SNRnorm. Similar to the
Groot et al., curve fitting was applied to the parameters
by using a power function (Eq. 2):
SNR norm;fit ¼ a p−d; ð2Þ
where a and d are fit parameters and p is the patient-
dependent parameter. The relative error between
SNRnorm and SNRfit was calculated for each data point
using (SNRfit−SNRnorm)/SNRfit × 100%, to perform
One-Way ANOVA test (α = 0.05) to determine signifi-
cant differences between the standard deviation of the
relative error distribution of the parameter fit with the
highest R2 and the other parameter fits [20].
To compare SNR between the median visual scores, a
Kruskal-Wallis test (α = 0.05) post hoc Dunn-Bonferroni
test was performed. The lesion detectability of all recon-
structions was compared with the 6 mbp by using a
non-parametric Friedman test (α = 0.05) and a post hoc
Dunn-Bonferroni test. Interobserver agreement for vis-
ual score and lesion detectability was quantified by
Fleiss’ kappa ( ) for multiple raters.
Combining Eq. 1 and 2, and substituting body mass
(m) for the patient-dependent parameter results in the
following expression for the DTP (MBq·min):
DTP ¼ SNR
2
a2
m2d; ð3Þ
where SNR is the acceptable noise level that was deter-
mined in the image analysis. Above this SNR value, all
scans scored as either moderate or good.
Results
Patient-dependent parameters
The measurements and calculations of the patient-
dependent parameters are displayed in Table 1.
Image quality
A repeated measures ANOVA (F (2.95, 1.79) = 0.27 p =
0.85) and additional post hoc test with Bonferroni cor-
rection (p > 0.05) revealed no significant differences in
liver SUVmean for 1-5 mbp reconstructions compared
with the 6 mbp reconstruction. Figure 1 demonstrates
the SNR and SNRnorm for the 1-6 mbp reconstructions.
Repeated measures ANOVA determined the mean SNR
(F (1.67, 29.76) = 180.54, p < 0.001) and mean SNRnorm
(F (1.95, 38.96) = 5.54, p = 0.008) and showed significant
differences in SNR and SNRnorm. The additional post
hoc tests using the Bonferroni correction revealed a sig-
nificantly lower (p < 0.001) mean SNR for all reconstruc-
tions compared with the 6 mbp as demonstrated in Fig.
1a. After normalization for administered activity and
time per bed position, the post hoc test with Bonferroni
correction showed no significant difference in mean
Table 1 Patient-dependent parameters
Parameters Mean ± SD Range
Body mass (kg) 86.5 ± 19.7 55–124
Body length (m) 1.74 ± 0.1 1.64–1.88
BMI (kg/m2) 28.3 ± 5.9 20.2–37.7
Body mass/body length (kg/m) 49.5 ± 10.6 33.3–69.3
Lean body mass (kg) 57.4 ± 11.7 37.2–76.4
Fig. 1 Boxplots of the SNR (a) and the SNRnorm (b) against the
mbp. Whiskers specify median, minimum, and maximum. Significant
differences compared with 6 mbp (a, p < 0.001; b, p < 0.05) are
indicated with an asterisk
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SNRnorm (p > 0.05) with the 6 mbp, except for 2 mbp
(p = 0.016) as shown in Fig. 1b.
After normalization of SNR, the mean of SNRnorm
over all the reconstructions was taken and correlated
with the described patient-dependent parameters. As
can be seen in Table 2, the linear fit of body mass with
mean SNRnorm shows the highest coefficient of deter-
mination (R2 = 0.60). The non-linear fits of the mean
SNRnorm with the patient-dependent parameters are il-
lustrated in Fig. 2. The fit parameters for body mass
were determined at a = 19.6 and d at 0.95 and R2 = 0.66.
The 95% confidence interval for parameter d was com-
puted at 0.62-1.27. A One-Way ANOVA test revealed
only a significant difference between the fit of body mass
and the fit of length (F (1, 40) = 235.8 p < 0.001).
Lesion quantification
A SSTR-positive lesion located centrally in the abdomen
was found in 16 patients. SUV measurements of these
lesions are presented in Table 3. A Friedman test was
performed for SUVmean and showed no significant dif-
ferences between the reconstructions (χ2 (5) = 3.49, p =
0.625). The same test was applied for SUVmax (χ2 (5) =
17.86, p = 0.03). The additional Dunn-Bonferroni post
hoc test revealed no significant difference between 1-5
mbp and 6 mbp reconstructions (p > 0.05). Also, a re-
peated measures ANOVA reported no significant differ-
ence for SUVpeak comparing the 1-5 mbp with the 6
mbp reference reconstruction (F (1.16, 17.45) = 0.84, p =
0.390).
Visual image quality
Table 4 gives an overview of the visual scores for each
reconstruction per reader. Overall, there was a fair
agreement between the three readers according to the
calculated Fleiss (0.34 (p < 0.001)), 95% CI (0.26-
0.42). As can be seen, only four scans were scored as
non-diagnostic by only one reader. Therefore, the me-
dian score of these individual visual scores revealed no
non-diagnostic score.
A Kruskal-Wallis test for comparing the other median
scores to the SNR showed highly significant differences
(χ2 (2) = 40.77, p < 0.001) in mean ranks of SNR
between visual score categories. A post hoc Dunn-
Bonferroni test revealed a strong significant difference
between poor and good (p < 0.001) and moderate and
good (p < 0.001) image quality. Between poor and mod-
erate, no significant difference (p = 0.405) was found
(Fig. 3). All scans with a SNR higher than 6.2 were
scored as either moderate or good.
Lesion detectability
The results of the lesion detectability assessment are
summarized in Table 5. It can be appreciated that the 2
mbp has a significant lower lesion detectability rate than
the other reconstructions compared with the 6 mbp. In
Fig. 4, a lesion located in the lower part of the left lung
is shown for a single patient. A Friedman test (χ2 (4) =
122.54, p < 0.001) with an additional Dunn-Bonferroni
post hoc test confirmed that only the 2 mbp had a sig-
nificant difference (p = 0.007) in lesion categories with
the 6 mbp reference reconstructions. Furthermore, the
table shows that the interobserver agreement was almost
perfect for 2 mbp (Fleiss = 0.81) and substantial
(Fleiss = 0.79-0.74) for the other reconstructions.
Constant image quality
Using an SNR of 6.2 as an acceptable noise level in the
PET images and the fitted values for a (19.6) and d
(0.95), the DTP needed for a more constant image qual-
ity as a function of body mass is given by Eq. 4:
DTP ¼ 0:10m1:9 ð4Þ
Discussion
The aim of this study was to investigate the influence of
patient-dependent parameters on 68Ga-DOTA-TATE
PET image quality and to propose a dose regimen that
maintains constant image quality while providing suffi-
cient image quality for clinical use. To the best of our
knowledge, this study is the first that investigates the re-
lationship between patient-dependent parameters and
68Ga-DOTA-TATE PET image quality.
The image quality analysis is based on liver SUVmean,
this value remained stable throughout all reconstruc-
tions. As expected, the image quality as measured by the
SNR in the liver increased with prolonged acquisition
time (Fig. 1a). After normalizing the SNR by the method
of de Groot et al. [20], the normalized image quality of 1
and 3-5 mbp shows no significant difference compared
with the 6 mbp reconstruction (Fig. 1b). Therefore, we
can conclude normalizing the SNR is a valid method to
quantify image quality independent of mbp.
In this study we found no significant changes in SUVs
of lesions with a SUVmean > 5.2 relative to the SUV-
mean (30.0 ± 29.3), SUVmax (42.1 ± 39.5), and SUVpeak
Table 2 Coefficients of determination obtained from the linear
correlations between the mean SNRnorm and the patient-
dependent parameters
Patient-dependent parameter R2
Body mass (kg) 0.60
Body mass/length (kg/m) 0.57
LBM (kg) 0.42
BMI (kg/m2) 0.50
Length (m) 0.18
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(32.0 ± 30.3) of 6 mbp reconstruction after reducing
PET acquisition time (Table 3). These results coincide
with the conclusions of 18F-FDG studies by Goethals
et al. [27] and Garcia-Velloso et al. [28], which also re-
ported no significant changes in SUV measurements be-
tween 1 mbp and longer acquisition times. Although
quantification of lesions with a lower uptake or low tar-
get to background ratio could be affected by reduced
count statistics, but this was not investigated in our
study. Furthermore, we have used a 3-mm Gaussian post
reconstruction filter together with a PSF recovery recon-
struction that is suitable for detecting smaller lesions. It
is known that these reconstructions are difficult to use
for harmonized quantification in a multi-center setting
[29, 30], since they show a higher recovery for smaller
lesions and suffer from possible overestimation of the
Fig. 2 Non-linear fits of the mean SNRnorm ((MBq·min)−1/2) versus body mass (a), length (b), body mass/length (c), BMI (d), and LBM (e). The
dashed lines represent the 95% confidence intervals of the fits
Table 3 Lesion semi-quantification
Reconstruction SUVmean (mean ± SD) SUVmax (mean ± SD) SUVpeak (mean ± SD)
1 mbp 31.8 ± 34.4 47.4 ± 49.7 33.5 ± 35.3
2 mbp 29.8 ± 28.0 44.0 ± 37.9 32.2 ± 29.1
3 mbp 29.8 ± 29.5 43.0 ± 40.3 32.0 ± 30.4
4 mbp 30.0 ± 29.6 42.5 ± 40.0 32.0 ± 30.5
5 mbp 29.7 ± 29.6 41.6 ± 39.5 31.6 ± 30.5
6 mbp 30.0 ± 29.3 42.1 ± 39.5 32.0 ± 30.3
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SUVmax due to the Gibb’s artifact [29]. For 18F-FDG, a
substantial larger filter of 7 mm was proposed to allow
PSF to fall within the limits currently set by the EANM
Research Ltd. (EARL) 18F-FDG PET/CT accreditation
program [30], possibly at the expense of decreased lesion
detectability. More research is needed for harmonized
quantification in 68Ga-DOTA-SSA imaging.
Correlation of patient-dependent parameters revealed
that body mass versus mean SNRnorm had the highest co-
efficient of determination (R2 = 0.60) for the linear fit
(Table 2) and showed the highest R2 (0.66) for the non-
linear fit (Fig. 2). However, the other fits for the patient
dependent parameters were not significantly different to
the body mass fit, except for patient length. Since body
mass is easy to use in practice, we used body mass to deter-
mine the optimal dose regimen. The non-linear fit with
body mass clarified 66% of variability in mean SNRnorm
between patients. The remaining 34% variability in
SNRnorm was not clarified in this study. This variability
might be caused by the difference in patient habitus, which
is not captured in the single body mass parameter. Al-
though, no difference in liver biodistribution (mean liver
SUVmean of 6 mbp 5.8 ± 1.3) between the reconstructions
was found. Variation could also be caused by possible (un-
known) liver inhomogeneities within the VOI. Neverthe-
less, the clarified variability is slightly lower but
comparable with findings by de Groot et al. [20] and
Menezes et al. [21]. In both 18F-FDG studies, body mass
also has the highest R2 with respectively SNRnorm (R2 =
0.77, Biograph mCT with OSEM3D + PSF + TOF recon-
struction) and the normalized coefficient of variation (R2 =
0.86, Biograph trueV with OSEM3D + PSF reconstruction).
However, they found that body mass was significantly su-
perior to some (de Groot et al.) and all (Menezes et al.)
other parameters, and these studies included more (re-
spectively 62 and 58) patients at random, but relatively few
patients at the extremes (< 60 kg and > 100 kg). The small
number of included patients is a major limitation of this
study. However, we have sampled different weights as
equally as possible through carefully selecting patients into
the described weight categories to optimize the weight dis-
tribution. The small number of patients included in the
current study results in a broad 95% confidence interval
for parameter d (0.62–1.27). However, it can be concluded
that a non-linear dose regimen is needed to achieve a more
constant image quality, since a linear dose regimen would
require a value of 0.5 for parameter d (Eq. 3). A number of
studies [12, 19, 21, 31, 32] used noise equivalent count rate
(NECR) data as a measure of PET image quality. The
NECR method is proposed to be more objective [12, 31,
32], as the liver SNR method might also be affected by vari-
ation in liver metabolism and reconstruction parameters.
Menezes et al. [21] used also NECR data, and also found
body mass as the parameter with the strongest correlation
(R2 = 0.72). Furthermore, using the NECR method, Wick-
ham et al. [12] developed a multivariate fit based on patient
sex, height, and weight for the Biograph mCT.
Table 4 Visual image quality and interobserver agreement
PET image quality Non-diagnostic Poor Moderate Good
Reconstruction Reader Reader Reader Reader
1 2 3 1 2 3 1 2 3 1 2 3
2mbp - - 4 5 15 14 14 6 2 2 - 1
3mbp - - - - 4 10 7 11 9 14 6 2
4mbp - - - - - 3 - 8 8 21 13 10
5mbp - - - - - - - 1 2 21 20 19
6mbp - - - - - - - - - 21 21 21
Overall interobserver agreement Fleiss of 0.34 (p < 0.001), 95%
CI (0.26-0.42)
Fig. 3 Boxplots of SNR against median visual score (non-diagnostic
(0), poor (1), moderate (2), or good (3)) with median and ranges.
Significant differences between poor-good and moderate-good (p <
0.001) are marked with an asterisk
Table 5 Number of body regions that were scored for lesion
detectability by three readers for each reconstruction and
interobserver agreement
Number of lesions Reconstruction
2 mbp* 3 mbp 4 mbp 5 mbp 6 mbp
0 139 133 128 127 126
1 29 25 30 31 29
2 17 19 11 9 11
3-5 23 28 35 34 35
6-10 19 21 21 21 20
>10 25 26 27 30 31
Interobserver agreement 0.81 0.79 0.76 0.74 0.74
Fleiss
Significant differences compared with 6 mbp (p < 0.001) are marked with
an asterisk
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The visual assessment of image quality revealed a fair
agreement between the three experienced readers. Com-
paring their median visual score to SNR resulted in an
SNR of 6.2 for sufficient image quality for clinical use. A
possible bias in visual scoring may have been introduced
by sequential scoring of the images from high to low
noise levels. In two previous 18F-FDG studies [20, 32],
SNRs of 9.6 and 10 respectively were determined as ac-
ceptable image quality. A reason for the lower SNR value
required for 68Ga-DOTA-TATE could be the higher
tumor-to-background ratio [33], due to the different bio-
distribution of the tracer compared with 18F-FDG [34].
Hence, findings for optimized image quality in 18F-FDG
imaging should not be translated directly to 68Ga-
DOTA-TATE PET imaging.
The required DTP for a more constant image quality as
a function of body mass is given in Eq. 4. It is assumed that
for clinical used dose regimens, the administered activity
and mbp can be chosen independently. However, increas-
ing the activity rather than the mbp will have a negative
impact on image quality, especially for higher count rates,
due to scanner and object dependent non-linear NECR
curves. Therefore, Machado et al. proposed to increase the
mbp for patients > 90 kg rather than increasing the
injected activity. They also observed a lower value for the
parameter d for smaller amounts of injected 18F-FDG that
was attributed to the difference in NECR. Furthermore,
enabling PSF and TOF affected the value of parameter d
[20, 30]. Machado et al. found a linear relationship be-
tween body mass and DTP using a PSF reconstruction and
a Gaussian post reconstruction filter of 7mm. The optimal
dose regimen in this study scales the body mass to the
power of 1.9. This is within the same range as found in
other studies (1.5-2.4) [12, 20, 30]. Values are difficult to
compare directly due to the use of a non-TOF scanner
(Machado et al.), differences in number of iterations (2-3)
and a different Gaussian filter (2_5mm).
Both NECR and liver SNR do not provide a complete
measure of image quality and do not yield adequate infor-
mation about image resolution and contrast recovery. Since
both are of key importance for lesion detectability, the
number of lesions observed by the physicians was analyzed.
The lesion detectability did not change for lower mbp re-
constructions, only the 2 mbp reconstruction revealed a
significantly (p = 0.007) lower lesion detectability compared
with the 6 mbp reference reconstructions. Similar to lesion
semi-quantification, lesion detectability was found to be still
reliable while decreasing DTP. As this study included pa-
tients with extensive disease it was not possible to count
every lesion separately in all patients on all reconstructions.
Therefore, we were limited to categorization of the number
of lesions. Consequently, a difference of one lesion between
reconstructions might occur within the same lesion cat-
egory in patients with multiple lesions in a certain body re-
gion. This differs from 18F-FDG and other 68Ga-DOTA-
SSA studies where the approach of counting the total
amount of lesions was used [8–10, 16, 17]. Another limita-
tion concerning lesion detectability is recognition bias that
can occur by the serial viewing of the reconstructions from
short to longer acquisition times.
Simulated shorter acquisition times did not affect
SUVs of lesions (SUVmean > 5.2) and lesion detectability
did not significantly differ for reconstructions longer
than 2 mbp. However, from the visual assessment ana-
lysis an SNR of 6.2 was determined acceptable. This re-
quires minimal 4 mbp (Fig. 1a) acquisition time for the
Fig. 4 Example of transversal PET/CT fusion and PET only images. The images show multiple lesions including one lesion in the liver and one
lesion with low uptake in the left basal lung (arrow). The lung lesion was detected on 3-6 mbp and was missed on 2 mbp. All other lesions were
detected on all mbps
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dose regimen used in this study. Hence, the subjective
assessment of image quality is the limiting factor for re-
ducing DTP.
As body mass has the greatest influence on the image
quality of 68Ga-DOTA-TATE PET scans, a dose regimen
based on the patient-dependent parameter body mass
(Eq. 4) is needed to maintain constant image quality
throughout the patient population. With an acquisition
time of 3 mbp, the activity range in the study population
would be 68MBq to 317MBq for patients weighing 55
to 124 kg. The current EANM guideline [14] recom-
mends an activity of at least 100MBq and up to 200
MBq, independent of patient habitus. This guideline
may result in unnecessarily high activity for patients with
low body mass (< 68 kg) or an unacceptable poor image
quality for patients with high body mass (> 98 kg) ac-
cording to our dose regimen in case of an acquisition
time of 3 mbp.
The proposed dose regimen is based on DTP
(MBq·min) instead of activity (MBq). The dose regimen
also allows for an increase in scan time to compensate for
a lower activity due to the decreasing elution output of a
68Ge/68Ga generator (half-life 270.8 days). This enables a
more cost-effective use of an expensive 68Ge/68Ga
generator.
Conclusion
Body mass can be used to predict 68Ga-DOTA-TATE
PET image quality. The proposed non-linear dose regi-
men based on body mass standardizes the image quality
while maintaining sufficient image quality for diagnosis.
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